Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study

OBJECTIVES: To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-axSpA (NCT01087762), an ongoing Phase 3 trial in patients with axial spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA). METHODS: Pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Landewé, R, Braun, J, Deodhar, A, Dougados, M, Maksymowych, W P, Mease, P J, Reveille, J D, Rudwaleit, M, van der Heijde, D, Stach, C, Hoepken, B, Fichtner, A, Coteur, G, de Longueville, M, Sieper, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2014
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888598/
https://www.ncbi.nlm.nih.gov/pubmed/24013647
http://dx.doi.org/10.1136/annrheumdis-2013-204231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888598/
https://www.ncbi.nlm.nih.gov/pubmed/24013647
http://dx.doi.org/10.1136/annrheumdis-2013-204231

Ejemplares similares